A PHASE 4, MULTICENTER, RANDOMIZED, DOUBLEBLIND, PLACEBO-CONTROLLED, PARALLEL-GROUP STUDY TO EVALUATE THE EFFICACY AND SAFETY OF APREMILAST (CC-10004) IN SUBJECTS WITH EARLY, OLIGOARTICULAR PSORIATIC ARTHRITIS DESPITE INITIAL STABLE TREATMENT WITH EITHER NSAIDS AND/OR = 1 CONVENTIONAL SYNTHETIC DMARD - FOREMOST

Celgene Corporation0 个研究点目标入组 330 人开始时间: 2018年10月23日最近更新: 2022年4月19日

适应症

试验速览

阶段: 1 期
状态: 进行中（未招募）
发起方: Celgene Corporation
入组人数: 330

研究概览入排标准研究者记录与标识符相似试验

研究概览

简要总结

暂无简介。

研究设计

研究类型: Interventional clinical trial of medicinal product

入排标准

性别: All

入选标准

•1. Subject is a male or female, = 18 years at time of consent.
•2. Subjects must understand and voluntarily sign an informed consent document prior to any study related assessments/procedures being conducted.
•3. Subject is willing and able to adhere to the study visit schedule and other protocol requirements.
•4. Subject must have a documented diagnosis of PsA (by any criteria) of = 3 months but 24 months duration at the time of the Screening Visit.
•5. Subject meets the CASPAR (Appendix B) criteria for PsA at the Screening Visit.
•6. Subject must have a total number of swollen joints greater than 1 and equal or less than 4 (> 1 but 4 swollen joints) at the Screening Visit and confirmed prior to randomization at the Baseline Visit.
•7. Subject must have a total number of tender joints greater than 1 and equal or less than 4 (> 1 but 4 tender joints) at Screening and confirmed prior to randomization at the Baseline Visit.
•8. Subjects taking oral glucocorticosteroids must be on a stable dose of prednisone = 10 mg/day or equivalent for at least 4 weeks prior to the Baseline Visit (Section 8.1).
•9. For all regions, the local Regulatory Label for treatment with apremilast must be followed. For example, subjects in the EU must have had inadequate response or intolerance to a prior csDMARD.
•10. Subjects taking 1 protocol-allowed csDMARD (methotrexate [MTX] or sulfasalazine [SSZ]) may enter the study provided that the duration of treatment is =6 months prior to the Baseline Visit and treatment is taken at a stable dose for at least 3 months prior to the Baseline Visit. See Permitted Medications (Section 8.1) for details describing dose criteria.
•11. Subjects exposed to MTX or SSZ and stopped treatment due to intolerance or due to safety reasons may enter the study provided that treatment was stopped within 4 days of the Baseline Visit.
•12. Subjects taking NSAIDs may enter the study provided that the dose is stable for at least 2 weeks prior to the Baseline Visit. Subjects may discontinue NSAIDs at any time up to and including the Baseline Visit, prior to study randomization.
•13. Females of childbearing potential (FCBP)† must have a negative pregnancy test at Screening and the Baseline Visit. While on investigational product and for at least 28 days after taking the last dose of investigational product, FCBP who engage in activity in which conception is possible must use one of the approved contraceptive options described below:
•Option 1: Any one of the following highly effective methods: hormonal contraception (oral, injection, implant, transdermal patch, vaginal ring); intrauterine device (IUD); tubal ligation; or partner’s vasectomy; OR
•Option 2: Male or female condom (latex condom or non-latex condom NOT made out of natural [animal] membrane [for example, polyurethane]); PLUS one additional barrier method: (a) diaphragm with spermicide; (b) cervical cap with spermicide; or (c) contraceptive sponge with spermicide.
•A female of childbearing potential is defined as a sexually mature female who: 1) has not undergone a
•hysterectomy (the surgical removal of the uterus) or bilateral oophorectomy (the surgical removal of both
•ovaries) or 2) has not been postmenopausal for at least 24 consecutive months (that is, has had menses at any
•time during the preceding 24 consecutive months).
•The female subject’s chosen form of contraception must be effective by the time the female subject is screened into the study (for example, hormonal co

排除标准

•1. Prior use of >1 cs DMARD.
•2. Prior exposure to a JAK-inhibitor and/or a biologic DMARD.
•3. Use of intra-articular (IA) glucocorticoid injection within 8 weeks before the Baseline Visit.
•4. Use of leflunomide within 12 weeks of randomization. Subjects who stopped leflunomide and completed 11 days of treatment with cholestyramine (8 g, 3 x daily) prior to the Baseline Visit may enter the study.
•5. Prior use of cyclosporine.
•6. Prior treatment with apremilast, or participation in a clinical study, involving apremilast.
•7. Use of any investigational drug within 4 weeks of the Baseline Visit, or 5 pharmacokinetic/pharmacodynamic half-lives, if known (whichever is longer).
•8. History of clinically significant or uncontrolled disease (as determined by the Investigator), including the presence of laboratory abnormalities, which places the subject at unacceptable risk if he/she were to participate in the study.
•9. Prior history of suicide attempt at any time in the subject’s lifetime prior to signing the informed consent, or major psychiatric illness requiring hospitalization within the last 3 years prior to signing the informed consent.
•10. Pregnant or breast feeding.
•11. Active substance abuse or a history of substance abuse within 6 months prior to Screening.
•12. History of allergy to any component of the investigational product.
•13. History of positive human immunodeficiency virus (HIV), or congenital or acquired immunodeficiency (eg, Common Variable Immunodeficiency Disease).
•14. Active tuberculosis or a history of incompletely treated tuberculosis.
•15. Bacterial infections requiring treatment with oral or injectable antibiotics, or significant viral or fungal infections, within 4 weeks of Screening. Any treatment for such infections must have been completed and the infection cured, at least 4 weeks prior to Screening and no new or recurrent infections prior to the Baseline Visit.
•16. Malignancy or history of malignancy or myeloproliferative or lymphoproliferative disease within the past 3 years, except for treated (ie, cured) basal cell or squamous cell in situ skin carcinomas.
•17. Major surgery (including joint surgery) within 8 weeks prior to the Screening Visit or planned major surgery within 6 months following the Baseline Visit.
•18. Rheumatic autoimmune disease other than PsA, including, but not limited to: systemic lupus erythematosus (SLE), mixed connective tissue disease (MCTD), scleroderma, polymyositis, or fibromyalgia.
•19. Prior history of or current inflammatory joint disease other than PsA (eg, gout, reactive arthritis, rheumatoid arthritis [RA], ankylosing spondylitis, Lyme disease), which confounds the ability to interpret data from the study.
•20. Erythrodermic, guttate, or generalized pustular psoriasis at randomization.

研究者

发起方

Celgene Corporation

相似试验

进行中（未招募）

1 期

A clinical study to test the effects of a apremilast compared to placebo for the treatment of patients with Psoriatic Arthritis with less than 2 years of duration and up to 4 joints involved, despite stable treatment with either non-steroidal anti-inflammatory drugs (ie aspirin, ibuprofen and naproxyn) and /or = 1 non-biologic disease-modifying antirheumatic drugs (methotrexate OR sulfasalazine).EARLY, OLIGOARTICULAR PSORIATIC ARTHRITISMedDRA version: 21.0Level: LLTClassification code 10037160Term: Psoriatic arthritisSystem Organ Class: 100000004859

EUCTR2018-002735-26-NLCelgene Corporation330

进行中（未招募）

1 期

EUCTR2018-002735-26-GBAmgen Inc.330

进行中（未招募）

1 期

EUCTR2018-002735-26-DEAmgen Inc.285

进行中（未招募）

1 期

EUCTR2018-002735-26-BEAmgen Inc.285

进行中（未招募）

1 期

A clinical study to test the effects of a apremilast compared to placebo for the treatment of patients with Psoriatic Arthritis with less than 2 years of duration and up to 4 joints involved, despite stable treatment with either non-steroidal anti-inflammatory drugs (ie aspirin, ibuprofen and naproxyn) and /or = 1 non-biologic disease-modifying antirheumatic drugs (methotrexate OR sulfasalazine).EARLY, OLIGOARTICULAR PSORIATIC ARTHRITISMedDRA version: 20.0 Level: LLT Classification code 10037160 Term: Psoriatic arthritis System Organ Class: 100000004859

EUCTR2018-002735-26-ESCelgene Corporation330